In a report released today, Michael Petusky from Barrington maintained a Buy rating on Haemonetics Corp (NYSE: HAE), with a price target of $127. The company’s shares opened today at $109.14, close to its 52-week high of $117.56.
“We believe that a full transition of the company’s 20,000 base could add $2 or more per plasma donation (i.e. $70 million plus).”
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 14.2% and a 59.2% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and DENTSPLY SIRONA Inc.
Haemonetics Corp has an analyst consensus of Strong Buy, with a price target consensus of $124.
Based on Haemonetics Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $2.82 million. In comparison, last year the company had a net profit of $20.1 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Haemonetics Corp. is a healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other.